Drugs that contain Aclidinium Bromide
1. List of Tudorza Pressair drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE46417 | ASTRAZENECA | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Feb, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6681768 | ASTRAZENECA | Powder formulation disintegrating system and method for dry powder inhalers |
Aug, 2022
(5 months ago) | |
| US8051851 | ASTRAZENECA | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(4 years from now) | |
| US10085974 | ASTRAZENECA | Dosage and formulation |
Mar, 2029
(6 years from now) | |
| US11000517 | ASTRAZENECA | Dosage and formulation |
Mar, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Mar 29, 2022 |
Market Authorisation Date: 23 July, 2012
Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)
Dosage: POWDER, METERED;INHALATION
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic